Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Prostatic Neoplasms | 33 | 2024 | 11126 | 2.280 |
Why?
|
Radium | 4 | 2024 | 65 | 2.050 |
Why?
|
Androgen Antagonists | 14 | 2014 | 1377 | 1.930 |
Why?
|
Bone Neoplasms | 16 | 2024 | 2530 | 1.720 |
Why?
|
Gonadotropin-Releasing Hormone | 7 | 2021 | 1206 | 1.300 |
Why?
|
RANK Ligand | 8 | 2014 | 326 | 1.110 |
Why?
|
Orchiectomy | 6 | 2023 | 474 | 0.940 |
Why?
|
Bone Diseases | 2 | 2020 | 416 | 0.910 |
Why?
|
Receptors, Androgen | 3 | 2024 | 1058 | 0.790 |
Why?
|
Antineoplastic Agents, Hormonal | 3 | 2013 | 1524 | 0.670 |
Why?
|
Teratoma | 2 | 2019 | 395 | 0.660 |
Why?
|
Adenocarcinoma | 5 | 2016 | 6364 | 0.610 |
Why?
|
Urinary Bladder Neoplasms | 6 | 2023 | 2249 | 0.580 |
Why?
|
Carcinoma, Renal Cell | 6 | 2024 | 3143 | 0.540 |
Why?
|
Bone Density Conservation Agents | 7 | 2014 | 772 | 0.530 |
Why?
|
Neurofibromin 1 | 1 | 2016 | 196 | 0.500 |
Why?
|
Informed Consent | 1 | 2021 | 995 | 0.500 |
Why?
|
Neck | 1 | 2019 | 698 | 0.490 |
Why?
|
Radiation Oncology | 1 | 2020 | 555 | 0.460 |
Why?
|
Pyrroles | 2 | 2012 | 1146 | 0.460 |
Why?
|
Testicular Neoplasms | 4 | 2023 | 806 | 0.450 |
Why?
|
Spinal Neoplasms | 4 | 2021 | 760 | 0.440 |
Why?
|
Kidney Neoplasms | 6 | 2022 | 4262 | 0.440 |
Why?
|
Castration | 1 | 2013 | 159 | 0.440 |
Why?
|
Bile Duct Diseases | 1 | 2013 | 100 | 0.430 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2013 | 841 | 0.420 |
Why?
|
Technetium Tc 99m Medronate | 1 | 2012 | 136 | 0.420 |
Why?
|
Bone Density | 4 | 2020 | 3468 | 0.400 |
Why?
|
Indoles | 2 | 2012 | 1839 | 0.400 |
Why?
|
Toremifene | 1 | 2011 | 24 | 0.400 |
Why?
|
Diphosphonates | 6 | 2014 | 623 | 0.400 |
Why?
|
Receptors, Fibroblast Growth Factor | 1 | 2012 | 185 | 0.390 |
Why?
|
Urogenital Neoplasms | 1 | 2012 | 137 | 0.390 |
Why?
|
Protein-Tyrosine Kinases | 3 | 2012 | 2455 | 0.390 |
Why?
|
Molecular Targeted Therapy | 2 | 2013 | 2725 | 0.390 |
Why?
|
Androstadienes | 1 | 2013 | 345 | 0.390 |
Why?
|
Leuprolide | 1 | 2012 | 321 | 0.370 |
Why?
|
Neoplasms, Hormone-Dependent | 1 | 2013 | 415 | 0.360 |
Why?
|
Fusion Proteins, gag-onc | 2 | 1998 | 3 | 0.340 |
Why?
|
Antibodies, Monoclonal | 7 | 2012 | 9274 | 0.340 |
Why?
|
Ontario | 2 | 2020 | 383 | 0.330 |
Why?
|
Androgens | 2 | 2013 | 1281 | 0.310 |
Why?
|
Multicenter Studies as Topic | 1 | 2013 | 1677 | 0.310 |
Why?
|
Tumor Lysis Syndrome | 1 | 2007 | 42 | 0.300 |
Why?
|
Thrombophilia | 1 | 2010 | 305 | 0.300 |
Why?
|
Fractures, Bone | 5 | 2014 | 1947 | 0.290 |
Why?
|
Male | 48 | 2024 | 350115 | 0.290 |
Why?
|
Radiopharmaceuticals | 4 | 2024 | 2645 | 0.280 |
Why?
|
Metabolic Diseases | 1 | 2013 | 658 | 0.270 |
Why?
|
Metabolome | 1 | 2012 | 895 | 0.260 |
Why?
|
Carcinoma | 2 | 2017 | 2375 | 0.250 |
Why?
|
Head and Neck Neoplasms | 1 | 2019 | 2736 | 0.250 |
Why?
|
Neovascularization, Physiologic | 1 | 2012 | 1351 | 0.240 |
Why?
|
Spinal Fractures | 1 | 2011 | 696 | 0.240 |
Why?
|
Osteoclasts | 4 | 2014 | 729 | 0.240 |
Why?
|
Receptors, Death Domain | 1 | 2024 | 32 | 0.240 |
Why?
|
Tumor Microenvironment | 7 | 2024 | 3590 | 0.240 |
Why?
|
Humans | 59 | 2024 | 744366 | 0.230 |
Why?
|
Imidazoles | 4 | 2014 | 1206 | 0.220 |
Why?
|
Seminoma | 1 | 2023 | 139 | 0.210 |
Why?
|
Angiogenesis Inhibitors | 1 | 2012 | 2038 | 0.200 |
Why?
|
Chemokine CCL20 | 1 | 2021 | 65 | 0.200 |
Why?
|
Neovascularization, Pathologic | 1 | 2012 | 2638 | 0.200 |
Why?
|
Receptors, CCR6 | 1 | 2021 | 81 | 0.200 |
Why?
|
Pituitary Apoplexy | 1 | 2021 | 30 | 0.200 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2007 | 643 | 0.190 |
Why?
|
Protein Kinase Inhibitors | 4 | 2013 | 5534 | 0.190 |
Why?
|
Neoplasm Proteins | 1 | 2013 | 3707 | 0.180 |
Why?
|
Prognosis | 5 | 2019 | 29060 | 0.180 |
Why?
|
Antineoplastic Agents | 4 | 2014 | 13693 | 0.180 |
Why?
|
Cystectomy | 3 | 2023 | 686 | 0.180 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2007 | 990 | 0.170 |
Why?
|
Randomized Controlled Trials as Topic | 2 | 2013 | 9955 | 0.170 |
Why?
|
Health Planning Guidelines | 1 | 2020 | 163 | 0.170 |
Why?
|
Interleukin-6 | 2 | 2024 | 3203 | 0.170 |
Why?
|
Magnesium | 2 | 1998 | 813 | 0.160 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 501 | 0.160 |
Why?
|
Neck Pain | 1 | 2019 | 180 | 0.150 |
Why?
|
Drug Delivery Systems | 1 | 2009 | 2219 | 0.150 |
Why?
|
Prostate-Specific Antigen | 4 | 2024 | 2494 | 0.150 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2012 | 5172 | 0.150 |
Why?
|
Microsatellite Instability | 1 | 2020 | 684 | 0.140 |
Why?
|
RNA Probes | 1 | 2016 | 113 | 0.140 |
Why?
|
Algorithms | 3 | 2019 | 13882 | 0.140 |
Why?
|
Genes, Neurofibromatosis 1 | 1 | 2016 | 79 | 0.140 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2023 | 808 | 0.140 |
Why?
|
Testis | 2 | 2018 | 804 | 0.140 |
Why?
|
Disease-Free Survival | 3 | 2017 | 6896 | 0.140 |
Why?
|
Neuroblastoma | 1 | 2024 | 1226 | 0.130 |
Why?
|
Neoplasms, Second Primary | 1 | 2023 | 1062 | 0.130 |
Why?
|
Choriocarcinoma | 1 | 2015 | 126 | 0.130 |
Why?
|
Mutagenesis, Site-Directed | 1 | 1998 | 1723 | 0.130 |
Why?
|
Edema | 1 | 2019 | 789 | 0.130 |
Why?
|
Watchful Waiting | 1 | 2019 | 492 | 0.120 |
Why?
|
Deoxycytidine | 1 | 2018 | 826 | 0.120 |
Why?
|
Osteoporosis | 3 | 2014 | 1579 | 0.120 |
Why?
|
Bone Marrow | 1 | 2024 | 2948 | 0.110 |
Why?
|
Insulin Resistance | 3 | 2013 | 3864 | 0.110 |
Why?
|
Cardiovascular Diseases | 4 | 2013 | 15160 | 0.110 |
Why?
|
Steroid 17-alpha-Hydroxylase | 1 | 2013 | 98 | 0.110 |
Why?
|
Aftercare | 1 | 2019 | 870 | 0.110 |
Why?
|
3-Methyl-2-Oxobutanoate Dehydrogenase (Lipoamide) | 1 | 2012 | 4 | 0.110 |
Why?
|
Radiography, Thoracic | 1 | 2019 | 1265 | 0.110 |
Why?
|
Prostatectomy | 2 | 2024 | 1890 | 0.110 |
Why?
|
Pituitary Neoplasms | 1 | 2021 | 1345 | 0.110 |
Why?
|
Up-Regulation | 1 | 2021 | 4222 | 0.100 |
Why?
|
In Situ Hybridization | 1 | 2016 | 1950 | 0.100 |
Why?
|
Hydroxybutyrates | 1 | 2012 | 82 | 0.100 |
Why?
|
Inflammation | 1 | 2012 | 10637 | 0.100 |
Why?
|
Adenosine Triphosphate | 1 | 1998 | 2027 | 0.100 |
Why?
|
Receptor Cross-Talk | 1 | 2012 | 119 | 0.100 |
Why?
|
RNA Splicing | 1 | 2016 | 908 | 0.100 |
Why?
|
Radiosurgery | 1 | 2021 | 1329 | 0.100 |
Why?
|
Protein Isoforms | 1 | 2016 | 1730 | 0.100 |
Why?
|
Aged | 14 | 2023 | 163288 | 0.100 |
Why?
|
Bone and Bones | 4 | 2019 | 2576 | 0.100 |
Why?
|
Urothelium | 1 | 2012 | 277 | 0.090 |
Why?
|
Adenoma | 1 | 2021 | 2174 | 0.090 |
Why?
|
Anilides | 1 | 2013 | 408 | 0.090 |
Why?
|
Bile Acids and Salts | 1 | 2012 | 368 | 0.090 |
Why?
|
Survival Rate | 3 | 2019 | 12788 | 0.090 |
Why?
|
Receptor Activator of Nuclear Factor-kappa B | 1 | 2009 | 79 | 0.090 |
Why?
|
Chemokine CXCL12 | 1 | 2012 | 465 | 0.090 |
Why?
|
Defibrillators, Implantable | 1 | 2019 | 1440 | 0.090 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2012 | 599 | 0.090 |
Why?
|
Aged, 80 and over | 6 | 2020 | 57776 | 0.090 |
Why?
|
Taxoids | 1 | 2013 | 666 | 0.090 |
Why?
|
Ultrasonography | 2 | 2019 | 5984 | 0.080 |
Why?
|
Diagnosis, Differential | 3 | 2019 | 12961 | 0.080 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2013 | 624 | 0.080 |
Why?
|
Interleukin-8 | 1 | 2012 | 690 | 0.080 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2024 | 9240 | 0.080 |
Why?
|
Cytokines | 1 | 2024 | 7323 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 552 | 0.080 |
Why?
|
Prospective Studies | 3 | 2024 | 53290 | 0.080 |
Why?
|
Single-Cell Analysis | 3 | 2024 | 2182 | 0.080 |
Why?
|
Incidence | 3 | 2013 | 20952 | 0.080 |
Why?
|
Radionuclide Imaging | 1 | 2012 | 2031 | 0.080 |
Why?
|
Risk Factors | 6 | 2017 | 72296 | 0.080 |
Why?
|
Prednisone | 1 | 2013 | 1574 | 0.080 |
Why?
|
Neoplasm Invasiveness | 3 | 2023 | 3616 | 0.080 |
Why?
|
Sarcopenia | 1 | 2013 | 368 | 0.080 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2021 | 4479 | 0.080 |
Why?
|
Kidney | 2 | 2022 | 7184 | 0.070 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2011 | 11726 | 0.070 |
Why?
|
Steroids | 1 | 2012 | 930 | 0.070 |
Why?
|
Oxidation-Reduction | 1 | 2012 | 2184 | 0.070 |
Why?
|
Treatment Failure | 1 | 2012 | 2618 | 0.070 |
Why?
|
Interleukin-1beta | 1 | 2012 | 972 | 0.070 |
Why?
|
Clinical Trials as Topic | 2 | 2014 | 7914 | 0.070 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 11525 | 0.060 |
Why?
|
Cisplatin | 2 | 2023 | 1662 | 0.060 |
Why?
|
Prostate | 2 | 2024 | 1775 | 0.060 |
Why?
|
Disease Models, Animal | 1 | 2024 | 18034 | 0.060 |
Why?
|
Cell Line, Tumor | 2 | 2021 | 16690 | 0.060 |
Why?
|
Middle Aged | 10 | 2020 | 213390 | 0.060 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2023 | 105 | 0.060 |
Why?
|
Lipid Metabolism | 1 | 2012 | 1889 | 0.060 |
Why?
|
Thromboembolism | 1 | 2010 | 987 | 0.060 |
Why?
|
Neoplasm Staging | 4 | 2023 | 11031 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 2 | 2019 | 20130 | 0.060 |
Why?
|
Diabetes Complications | 1 | 2010 | 1359 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2007 | 1851 | 0.050 |
Why?
|
Practice Guidelines as Topic | 1 | 2019 | 7282 | 0.050 |
Why?
|
Neoplasms | 1 | 2011 | 21696 | 0.050 |
Why?
|
Enzyme Inhibitors | 1 | 2013 | 3799 | 0.050 |
Why?
|
Animals | 5 | 2024 | 168768 | 0.050 |
Why?
|
Dyslipidemias | 1 | 2009 | 849 | 0.050 |
Why?
|
Pyridines | 1 | 2013 | 2825 | 0.050 |
Why?
|
Retrospective Studies | 7 | 2024 | 77460 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2012 | 3511 | 0.050 |
Why?
|
Kinetics | 2 | 1998 | 6476 | 0.050 |
Why?
|
Diagnostic Imaging | 2 | 2014 | 3508 | 0.050 |
Why?
|
Liver | 1 | 2015 | 7475 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2015 | 4253 | 0.040 |
Why?
|
Mutation | 3 | 2024 | 29786 | 0.040 |
Why?
|
Binding Sites | 2 | 1998 | 6111 | 0.040 |
Why?
|
Administration, Oral | 1 | 2007 | 3914 | 0.040 |
Why?
|
Mice | 2 | 2024 | 81201 | 0.040 |
Why?
|
Spermatocele | 1 | 2018 | 9 | 0.040 |
Why?
|
Varicocele | 1 | 2018 | 78 | 0.040 |
Why?
|
Treatment Outcome | 6 | 2023 | 63107 | 0.040 |
Why?
|
Stromal Cells | 1 | 2024 | 1355 | 0.040 |
Why?
|
Viscosity | 1 | 1998 | 328 | 0.040 |
Why?
|
Muscles | 1 | 2023 | 1614 | 0.040 |
Why?
|
Risk Assessment | 2 | 2010 | 23336 | 0.040 |
Why?
|
Health Promotion | 1 | 2010 | 2205 | 0.040 |
Why?
|
Solvents | 1 | 1998 | 302 | 0.040 |
Why?
|
Salvage Therapy | 1 | 2024 | 1275 | 0.040 |
Why?
|
Double-Blind Method | 1 | 2011 | 12025 | 0.040 |
Why?
|
Gene Expression Profiling | 2 | 2024 | 9445 | 0.040 |
Why?
|
Urinary Bladder | 1 | 2023 | 1173 | 0.040 |
Why?
|
Myeloid Cells | 1 | 2021 | 810 | 0.040 |
Why?
|
Chickens | 1 | 1998 | 865 | 0.040 |
Why?
|
Genes, Tumor Suppressor | 1 | 2021 | 1097 | 0.040 |
Why?
|
Propensity Score | 1 | 2023 | 1781 | 0.030 |
Why?
|
Health Status | 1 | 2009 | 4034 | 0.030 |
Why?
|
Urologic Surgical Procedures | 1 | 2018 | 302 | 0.030 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2021 | 1038 | 0.030 |
Why?
|
BRCA2 Protein | 1 | 2020 | 794 | 0.030 |
Why?
|
Female | 7 | 2023 | 380193 | 0.030 |
Why?
|
Gynecomastia | 1 | 2015 | 88 | 0.030 |
Why?
|
Signal Transduction | 2 | 2024 | 23404 | 0.030 |
Why?
|
Alpha Particles | 1 | 2014 | 26 | 0.030 |
Why?
|
Osteoblasts | 2 | 2010 | 1166 | 0.030 |
Why?
|
Substrate Specificity | 1 | 1998 | 1802 | 0.030 |
Why?
|
Fluorouracil | 1 | 2018 | 1619 | 0.030 |
Why?
|
Incidental Findings | 1 | 2018 | 689 | 0.030 |
Why?
|
Chorionic Gonadotropin | 1 | 2015 | 476 | 0.030 |
Why?
|
BRCA1 Protein | 1 | 2020 | 1149 | 0.030 |
Why?
|
Hyperthyroidism | 1 | 2015 | 295 | 0.030 |
Why?
|
Spine | 1 | 2020 | 1144 | 0.030 |
Why?
|
Radioisotopes | 1 | 2014 | 500 | 0.030 |
Why?
|
Translocation, Genetic | 1 | 2018 | 1420 | 0.030 |
Why?
|
Young Adult | 2 | 2016 | 56429 | 0.030 |
Why?
|
Fractures, Spontaneous | 1 | 2014 | 230 | 0.030 |
Why?
|
Enzyme Activation | 1 | 1998 | 3702 | 0.030 |
Why?
|
Cattle | 1 | 1998 | 3922 | 0.030 |
Why?
|
Hospitals, General | 1 | 2017 | 749 | 0.030 |
Why?
|
Rabbits | 1 | 1998 | 4894 | 0.030 |
Why?
|
United States | 1 | 2020 | 69872 | 0.030 |
Why?
|
Adult | 3 | 2022 | 214052 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 1998 | 3848 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2009 | 5749 | 0.020 |
Why?
|
Obesity | 1 | 2013 | 12746 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3480 | 0.020 |
Why?
|
Coronary Artery Disease | 1 | 2010 | 6486 | 0.020 |
Why?
|
Endothelial Cells | 1 | 2022 | 3486 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2019 | 4851 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 1998 | 6621 | 0.020 |
Why?
|
Fatigue | 1 | 2015 | 1531 | 0.020 |
Why?
|
Neurosurgical Procedures | 1 | 2019 | 2002 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5717 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2019 | 8642 | 0.020 |
Why?
|
Phosphorylation | 1 | 1998 | 8436 | 0.020 |
Why?
|
Macrophages | 1 | 2021 | 5660 | 0.020 |
Why?
|
Time Factors | 2 | 2019 | 40075 | 0.020 |
Why?
|
Survivors | 1 | 2017 | 2291 | 0.020 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 934 | 0.020 |
Why?
|
Protein Binding | 1 | 1998 | 9384 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2017 | 6539 | 0.020 |
Why?
|
Peptide Fragments | 1 | 1998 | 5096 | 0.020 |
Why?
|
Patient Care Planning | 1 | 2011 | 921 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2021 | 8432 | 0.020 |
Why?
|
Weight Loss | 1 | 2015 | 2625 | 0.020 |
Why?
|
T-Lymphocytes | 1 | 2021 | 10183 | 0.010 |
Why?
|
Boston | 1 | 2017 | 9312 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2021 | 21748 | 0.010 |
Why?
|
Phenotype | 1 | 2021 | 16367 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2019 | 15078 | 0.010 |
Why?
|
Lymphatic Metastasis | 1 | 2011 | 2924 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2017 | 12244 | 0.010 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3135 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2017 | 12356 | 0.010 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3242 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2019 | 19905 | 0.010 |
Why?
|
Pandemics | 1 | 2020 | 8385 | 0.010 |
Why?
|
Disease Progression | 1 | 2014 | 13286 | 0.010 |
Why?
|
Lung | 1 | 2015 | 9857 | 0.010 |
Why?
|
Child | 1 | 2024 | 77709 | 0.010 |
Why?
|
Cohort Studies | 1 | 2013 | 40559 | 0.010 |
Why?
|